<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462617</url>
  </required_header>
  <id_info>
    <org_study_id>115117</org_study_id>
    <nct_id>NCT01462617</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability, Pharmacokinetics &amp; Pharmacodynamics of Single &amp; Repeat Doses of GSK2269557</brief_title>
  <official_title>A Single-centre. Double-blind, Placebo Controlled Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Repeat Doses of Nebulised GSK2269557 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will comprise three Parts:&#xD;
&#xD;
      Part A will consist of two cohorts of healthy male volunteers to assess the safety,&#xD;
      tolerability and pharmacokinetics of ascending single doses of nebulised GSK2269557. Blinded&#xD;
      safety and available PK data will be reviewed before each dose escalation.&#xD;
&#xD;
      Part B will be one cohort to examine the safety, tolerability and pharmacokinetics of a&#xD;
      repeated dose of GSK2269557 given by nebuliser for 7 days in healthy male volunteers. The&#xD;
      total daily dose will be the same as, or lower than, doses that are well tolerated in Part A.&#xD;
&#xD;
      Part C will consist of two cohorts of single nebulised doses in healthy male smokers, to&#xD;
      assess pharmacodynamic endpoints in sputum and bronchoalveolar lavage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2011</start_date>
  <completion_date type="Actual">March 26, 2012</completion_date>
  <primary_completion_date type="Actual">March 26, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical monitoring of blood pressure and pulse rate</measure>
    <time_frame>Day 1 until Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical monitoring of cardiac parameters</measure>
    <time_frame>Day 1 until Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical monitoring of lung function</measure>
    <time_frame>Day 1 until Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical monitoring of safety laboratory data</measure>
    <time_frame>Day 1 until Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical monitoring of adverse events</measure>
    <time_frame>Day 1 until Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile at predose, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 hours post-dose. Profile to include Cmas, Area Under the Curve, Tmax</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD bimoarkers potentially to incldue PIP3, Akt, S6K, IFNy, IgE, CD62L and CD44.</measure>
    <time_frame>Day 1 to Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Pi3K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Pi3K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557 matching placebo</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included at the&#xD;
             Investigator's discretion provided the abnormality will not jeopardize subject safety&#xD;
             or study integrity .&#xD;
&#xD;
          -  Male between 18 and 55 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Subjects with female partners of child-bearing potential must agree to use one of the&#xD;
             contraception methods listed in Section 8.1. This criterion must be followed from the&#xD;
             time of the first dose of study medication until the follow up visit.&#xD;
&#xD;
          -  Body weight greater than or equal to 55kg and BMI within the range 18-31 kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Average QTcB &lt; 450 msec&#xD;
&#xD;
          -  AST and ALT &lt; 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN&#xD;
             (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin &lt;35%).&#xD;
&#xD;
        Additional inclusion criteria for healthy smokers Cohorts 4-5 (Part C)&#xD;
&#xD;
          -  Subjects who are current smokers. Must have smoked in the 12-month period preceding&#xD;
             the screening visit and have a pack history of greater than or equal to 5 pack years.&#xD;
             [number of pack years = (number of cigarettes per day/20) x number of years smoked].&#xD;
&#xD;
          -  Normal spirometry (FEV1 greater than or equal to 80% of predicted, FEV1/FVC ratio&#xD;
             greater than or equal to 70%) at screening. Predictions should be according to ECCS&#xD;
             equations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A history of congestive heart failure, coronary insufficiency or cardiac arrhythmia or&#xD;
             a finding on screening 24h Holter monitor that would contraindicate the subject's&#xD;
             participation in the study.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as:&#xD;
&#xD;
             â€¢ an average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit&#xD;
             is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of&#xD;
             wine or 1 (25 ml) measure of spirits.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 90 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  The subject has received any type of vaccination within 3 weeks of their first dose of&#xD;
             investigational product, or are expected to be vaccinated within 3 weeks after their&#xD;
             last dose of investigational product.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy (including atopic asthma) that, in the opinion of the&#xD;
             investigator or GSK Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 90 day period.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nemiralisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115117</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

